Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc.verified

MRTX

Price:

$58.7

Market Cap:

$4.12B

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Thera...[Read more]

Industry

Biotechnology

IPO Date

2013-07-15

Stock Exchange

NASDAQ

Ticker

MRTX

The PE Ratio as of May 2024 (TTM) for Mirati Therapeutics, Inc. (MRTX) is -4.82

According to Mirati Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -4.82. This represents a change of 41.25% compared to the average of -3.41 of the last 4 quarters.

Mirati Therapeutics, Inc. (MRTX) Historical PE Ratio (quarterly & annually)

How has MRTX PE Ratio performed in the past?

The mean historical PE Ratio of Mirati Therapeutics, Inc. over the last ten years is -10.53. The current -4.82 PE Ratio has changed 4.47% with respect to the historical average. Over the past ten years (40 quarters), MRTX's PE Ratio was at its highest in in the December 2016 quarter at -1.20. The PE Ratio was at its lowest in in the September 2021 quarter at -28.54.

Quarterly (TTM)
Annual

Average

-10.53

Median

-7.41

Minimum

-27.65

Maximum

-1.13

Mirati Therapeutics, Inc. (MRTX) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Mirati Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 479.26%

Maximum Annual PE Ratio = -1.13

Minimum Annual Increase = -86.35%

Minimum Annual PE Ratio = -27.65

Quarterly (TTM)
Annual
YearPE RatioChange
2022-3.44-73.71%
2021-13.08-52.68%
2020-27.6521.73%
2019-22.7170.53%
2018-13.32103.38%
2017-6.55479.26%
2016-1.13-86.35%
2015-8.2844.85%
2014-5.7264.36%
2013-3.480.86%

Mirati Therapeutics, Inc. (MRTX) Average PE Ratio

How has MRTX PE Ratio performed in the past?

The current PE Ratio of Mirati Therapeutics, Inc. (MRTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-14.72

5-year avg

-16.04

10-year avg

-10.53

Mirati Therapeutics, Inc. (MRTX) PE Ratio vs. Peers

How is MRTX’s PE Ratio compared to its peers?

Mirati Therapeutics, Inc.’s PE Ratio is greater than Reata Pharmaceuticals, Inc. (-89.36), less than Sarepta Therapeutics, Inc. (686.76), less than Krystal Biotech, Inc. (80.60), greater than Intercept Pharmaceuticals, Inc. (-13.55), greater than Day One Biopharmaceuticals, Inc. (-5.71), less than Amylyx Pharmaceuticals, Inc. (-1.65), greater than Terns Pharmaceuticals, Inc. (-4.90), greater than Apellis Pharmaceuticals, Inc. (-11.97), less than Madrigal Pharmaceuticals, Inc. (0), greater than Viking Therapeutics, Inc. (-10.34), greater than Hepion Pharmaceuticals, Inc. (-69.27), less than PTC Therapeutics, Inc. (-0.15), greater than Akero Therapeutics, Inc. (-4.91), greater than null (-6.06),

Build a custom stock screener for Mirati Therapeutics, Inc. (MRTX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Mirati Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Mirati Therapeutics, Inc. (MRTX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Mirati Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Mirati Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for Mirati Therapeutics, Inc. (MRTX)?

What is the highest PE Ratio for Mirati Therapeutics, Inc. (MRTX)?

What is the 3-year average PE Ratio for Mirati Therapeutics, Inc. (MRTX)?

What is the 5-year average PE Ratio for Mirati Therapeutics, Inc. (MRTX)?

How does the current PE Ratio for Mirati Therapeutics, Inc. (MRTX) compare to its historical average?